IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
10 Apr, 2012, 09:58 ET
NEW YORK, April 10, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC.PK) announced today that the Company has signed a technology licensing agreement with Stem Cells 21 of Thailand, http://www.StemCells21.com. Stem Cells 21 is led by Dr. Chatchai Sribundit MD, a fellow of the College of Anti-ageing Medicine and a member of the National Olympic Committee and Mr. Paul Collier, the Managing Director for the Stem Cells 21. They have been in the cellular treatment business for over 11 years in Thailand and have a vast amount of experience. They run the Absolute Health Integrative Medical Center in Bangkok. In partnership with clinics and hospitals, they manage patient care for foreigners traveling to Thailand for medical care. Their partner laboratories and physicians have developed a range of treatment protocols using either umbilical cord blood-derived adult stem cells or adipose-derived cells, from the patient's own body for a wide variety of progressive and debilitating diseases.
Dr. Steven Victor, Chairman of IntelliCell BioSciences stated, "We are excited to sign this technology licensing agreement in Thailand with Stem Cells 21. With Dr. Chatchai Sribundit and Mr. Paul Collier's extensive experience in cellular therapy, our technology can be utilized to its fullest potential. We look forward to working with Stem Cells 21 and the Absolute Health Integrative Medical Center in Bangkok to advance the science of adult autologous vascular cellular therapy in Thailand."
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (HCT/P's) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to enter into technology licensing agreements that cover a particular international territory or country.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact: [email protected]
SOURCE IntelliCell BioSciences, Inc.
Share this article